A large options trade hit Humana (HUM) with a June 18, 2026 $235 call sweep bought on the ask, signaling aggressive positioning. The trade showed 2,831 contracts in total volume compared to just 88 contracts in open interest, producing a very elevated V/OI ratio of about 32.2X. That means the day’s activity was far larger than the existing open interest, suggesting this may represent fresh positioning rather than simply closing or rolling an existing trade.
The buyer paid $16 per contract, with the trade showing a sizable $4.4 million premium tied to the sweep. With HUM trading around $235.42 at the time of execution, the $235 strike is essentially at-the-money. The contract has roughly 50 days until expiration, giving the position a moderate time window for the stock to move. Overall, the combination of ask-side buying, a large premium, and unusually high volume versus open interest points to a notable options signal in HUM.
Volume and Open Interest Data
The volume and open interest data for the HUM $235 call expiring 06/18/2026 shows a major surge in activity on 04/29/26. On that day, 3,204 contracts traded versus only 88 open interest. This creates a very high volume-to-open-interest ratio of about 36.4X. This indicates the day’s trading volume was far above the existing positioning and may point to fresh demand.
The contract price also climbed sharply, rising from $8.80 on 04/27 to $15.14 on 04/28. It then closed at $17.25 on 04/29, while implied volatility cooled from 50.22% to 42.99% on the latest day. Overall, the spike in call volume, small but rising open interest, and higher contract price suggest unusually strong interest in exposure for HUM.
What’s Happening with HUM
Humana’s recent activity has centered on stabilizing its Medicare Advantage business while shoring up its balance sheet and reaffirming guidance after a difficult 2025. In February 2026, the company reported fourth-quarter 2025 results showing a GAAP net loss per share of 6.61 dollars and an adjusted net loss per share of 3.96 dollars. However, full-year 2025 adjusted EPS of 17.14 dollars came in line with management’s expectations, framing the loss as a reset year driven by elevated medical costs.
On April 29th, 2026, Humana reported first-quarter 2026 earnings of about 10.31 dollars per share on revenue of roughly 32.4 billion dollars. These results beat EPS and revenue estimates and affirmed its full-year 2026 adjusted guidance. This has helped ease some investor concerns about profitability and medical cost trends.
Strategically, the company has moved to strengthen its capital structure with a 1 billion dollar junior subordinated notes offering due 2056, added healthcare investor Robert S. Field to its board. It has also highlighted growth and innovation in its CenterWell care delivery platform and broader community impact in its 2025 Impact Report.
About HUM
Humana Inc. is a major U.S. health insurance and healthcare services company focused primarily on Medicare Advantage, Medicare prescription drug plans, and other government-sponsored health benefit programs. The company provides medical, pharmacy, dental, vision, and supplemental insurance products, while also operating care delivery and wellness services aimed at helping members manage their health. Humana’s business is especially tied to the aging U.S. population and demand for Medicare-related coverage, making it one of the key players in the managed healthcare industry.
Analyst Ratings
| Firm | Updated | Rating / Signal |
|---|---|---|
| CFRA | 04/26/2026 | 3 stars |
| Market Edge | 04/16/2026 | Long |
| Argus | 04/06/2026 | Hold |
| Morningstar | 04/07/2026 | 4 stars |
| LSEG | 04/28/2026 | Hold |
| Schwab Equity Ratings | 04/28/2026 | F |
The analyst ratings snapshot for Humana (HUM) shows a mixed outlook. Market Edge is the most bullish with a Longrating, while Morningstar also leans positive with a 4-star rating. However, several firms remain cautious, including Argus and LSEG, both assigning Hold ratings, while CFRA’s 3-star score suggests a neutral view.
The weakest signal comes from Schwab Equity Ratings, which gives HUM an F, pointing to a notably bearish assessment. Overall, the ratings picture is divided, with some positive sentiment offset by neutral recommendations and one strongly negative score.
Want to see more of these trades? Try out Cheddar Flow free for 7 days. Learn More
Disclaimer: Options trading involves significant risk and is not suitable for all investors. You may lose the entire investment, and certain strategies may result in losses exceeding the initial amount invested. Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice. Always consult a financial or tax advisor before making investment decisions.
